Point72 Asset Management L.P. Increases Stock Position in Cellectis SA (NASDAQ:CLLS)

Point72 Asset Management L.P. boosted its position in shares of Cellectis SA (NASDAQ:CLLS) by 32.6% in the third quarter, Holdings Channel.com reports. The firm owned 189,000 shares of the biotechnology company’s stock after acquiring an additional 46,500 shares during the period. Point72 Asset Management L.P.’s holdings in Cellectis were worth $1,966,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. A.R.T. Advisors LLC acquired a new position in Cellectis in the second quarter worth $171,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Cellectis by 8.6% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,314,295 shares of the biotechnology company’s stock worth $13,669,000 after buying an additional 104,276 shares in the last quarter. Morgan Stanley lifted its stake in shares of Cellectis by 56.6% in the 2nd quarter. Morgan Stanley now owns 494,775 shares of the biotechnology company’s stock worth $7,719,000 after acquiring an additional 178,865 shares during the period. Nikko Asset Management Americas Inc. lifted its stake in shares of Cellectis by 7.3% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 1,314,295 shares of the biotechnology company’s stock worth $13,669,000 after acquiring an additional 89,961 shares during the period. Finally, Aperio Group LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $147,000. 30.97% of the stock is currently owned by institutional investors and hedge funds.

Cellectis stock opened at $14.47 on Wednesday. The company has a current ratio of 7.99, a quick ratio of 7.93 and a debt-to-equity ratio of 0.12. Cellectis SA has a 1-year low of $9.50 and a 1-year high of $22.47. The firm’s fifty day simple moving average is $12.39 and its 200-day simple moving average is $13.58. The company has a market capitalization of $590.05 million, a P/E ratio of -7.50 and a beta of 1.82.

A number of research firms recently weighed in on CLLS. BTIG Research assumed coverage on Cellectis in a research report on Friday, August 9th. They issued a “buy” rating and a $37.00 price target for the company. BidaskClub upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Tuesday, November 12th. Finally, Goldman Sachs Group set a $20.00 target price on Cellectis and gave the company a “hold” rating in a research note on Monday, August 12th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $28.80.

Cellectis Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Recommended Story: Backdoor Roth IRA

Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).

Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit